1. SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB‐3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017) Authors: Tam, C.S.; Quach, H.; Nicol, A.; Badoux, X.; Rose, H.; Prince, H.; Leahy, M.F.; Eek, R.; Wickham, N.; Patil, S.; Huang, J.; Zhang, X.; Wang, L.; Hedrick, E.; Novotny, W.; Flinn, I. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL). (12th June 2019) Authors: Tam, C.S.; Quach, H.; Nicol, A.; Badoux, X.; Rose, H.; Prince, H.M.; Leahy, M.F.; Eek, R.; Wickham, N.; Patil, S.S.; Huang, J.; Prathikanti, R.; Wang, L.; Reed, W.; Flinn, I.W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗